Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy

Journal of Clinical Oncology

Volumn 18, Issue 10, 2000, Pages 2143-2151

  Capuron, Lucile ^a   Ravaud, Alain ^a   Dantzer, Robert ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ANXIETY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DEPRESSION; DRUG EFFECT; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MELANOMA; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0034079672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.10.2143     Document Type: Article

References (46)

1. Kirkwood JM, Strawderman MH, Ernstoff MS. et al: Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial. J Clin Oncol 14:7-17, 1996
2. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med 316:889-897, 1987
3. Sleijfer DT, Janssen RA, Buter J, et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119-1123, 1992
4. Négrier S, Escudier B, Lasset C, et al: Interleukin-2, Interferon or both in 425 patients with metastatic renal cell cancer: Results of a multicenter randomized trial. N Engl J Med 338:1272-1278, 1998
5. Ravaud A, Debled M: Present achievements in the medical treatment of metastatic renal cell carcinoma. Crit Rev Oncol Hematol 31:77-87, 1999
6. Fenner MH, Hanninen EL, Kirchner HH, et al: Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha. Lancet 341:372, 1993 (letter)
7. Ravaud A, Négrier S, Lakdja F, et al: Effets secondaires de l'interleukine-2. Bull Cancer 78:989-1005, 1991
8. Ravaud A, Bedane C, Geoffrois L, et al: Toxicity and feasibility of adjuvant high dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer 80:1767-1769, 1999
9. Plata Salaman CR: Immunoregulators in the nervous system. Neurosci Biobehav Rev 15:185-215, 1991
10. Dantzer R, Bluthé RM, Layé S, et al: Cytokines and sickness behavior. Ann N Y Acad Sci 840:586-590, 1998
11. Kluger M: Fever: Role of pyrogens and cryogens. Physiol Rev 71:93-127, 1991
12. Besedovsky HO, Del Rey AE, Sorkin E: Immune-neuroendocrine interactions. J Immunol 135:817-822, 1985
13. Buckingham JC, Loxley HD, Christian HC, et al: Activation of the HPA axis by immune insults: Roles and interactions of cytokines, eicosanoids, and glucocorticoids. Pharmacol Biochem Behav 54:285-298, 1996
14. Anisman H, Merali Z: Anhedonic and anxiogenic effects of cytokine exposure, in Dantzer R, Wollman EE, Yirmiya R (eds): Cytokines, Stress and Depression. New York, NY, Plenum, 1999, pp 199-233
15. Dantzer R, Bluthé RM, Kent S, et al: Behavioral effects of cytokines: An insight into mechanisms of sickness behavior, in De Souza (ed): Neurobiology of Cytokines: Part B. San Diego, CA, Academic Press, 1993, pp 130-150
16. Hopkins SJ, Rothwell NJ: Cytokines and the nervous system: I. Expression and recognition. Trends Neurosci 18:83-88, 1995
17. Rothwell NJ, Hopkins SJ: Cytokines and the nervous system: II. Actions and mechanisms of action. Trends Neurosci 18:130-136, 1995
18. Capuron L, Ravaud A: Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 340:1370, 1999 (letter)
19. Denicoff KD, Rubinow DR, Papa MZ, et al: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293-300, 1987
20. Valentine AD, Meyers CA, Kling MA, et al: Mood and cognitive side effects of interferon-alfa therapy. Semin Oncol 25:39-47, 1998 (suppl 1)
21. Meyers CA: Mood and cognitive disorders in cancer patients receiving cytokine therapy, in Dantzer R, Wollman EE, Yirmiya R (eds): Cytokines, Stress and Depression. New York, NY, Plenum, 1999, pp 75-81
22. Yirmiya R: Endotoxin produces a depressive-like episode in rats. Brain Res 711:163-174, 1996
23. Anisman H, Kokkinidis L, Borowski T, et al: Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 779:177-187, 1998
24. Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147:1477-1580, 1987
25. Négrier S, Ravaud A, Delva R, et al: Combination of cytokines in metastatic renal cell carcinoma: Is the subcutaneous route less active than the intravenous route? Proc Am Soc Clin Oncol 18:331a, 1999 (abstr 1273)
26. World Health Organization: Handbook for Reporting Results of Cancer Treatment [WHO publication no. 48]. Geneva, Switzerland, World Health Organization, 1979
27. Montgomery SA, Asberg A: A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389, 1979
28. Covi L, Lipman R, McNair DM, et al: Symptomatic volunteers in multicenter drug trials. Prog Neuropsychopharmacol 3:521-533, 1979
29. Bouvard M, Cottraux J: Echelle de dépression de Montgomery et Asberg, in Cottraux J (ed): Protocoles et Échelles d'Évaluation en Psychiatrie et en Psychologie. Paris, France, Masson, 1998, pp 139-141
30. Pellet J, Faure F, Lang F, et al: Etude de l'échelle de ralentissement sur un échantillon de sujets non ralentis, non déprimés. Psychol Med 18:1017-1020, 1986
31. Smith JH, Khayat D: Residual acute confusional and hallucinatory syndromes induced by interleukin-2/alfa-interferon treatment. Psychooncology 1:115-118, 1992
32. Miller A, Musselman D, Penna S, et al: Pretreatment with the antidepressant paroxetine prevents cytokine-induced depression during interferon-alpha therapy for malignant melanoma. Neuroimmuno-modulation 6:237, 1999 (abstr)
33. Walker LG, Wesnes KP, Heys SD, et al: The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerised assessments. Eur J Cancer 32A:2275-2283, 1996
34. Walker LG, Walker MB, Heys SD, et al: The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial. Psychooncology 6:290-301, 1997
35. Pavol MA, Meyers CA, Rexer JL, et al: Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 45:947-950, 1995
36. Hunt CM, Dominitz JA, Bute BP, et al: Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 42:2482-2486, 1997
37. Goldberg RJ: Diagnostic dilemmas presented by patients with anxiety and depression. Am J Med 98:278-284, 1995
38. Lecrubier Y: Echelle de gravité de l'anxiété de Covi, in Guelfi JD (ed): L'Évaluation Clinique Standardisée en Psychiatrie. Boulogne, France, Pierre Fabre, 1997, pp 303-307
39. Anisman H, Kokkinidis L, Merali Z: Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res 731:1-11, 1996
40. Hanisch UK, Seto D, Quirion R: Modulation of hippocampal acetylcholine release: A potent central action of interleukin-2. J Neurosci 13:3368-3374, 1993
41. Dunn AL, Crnic LS: Repeated injections of interferon-alpha A/D in Balb/c mice: Behavioral effects. Brain Behav Immun 7:104-111, 1993
42. Crnic LS, Segall MA: Prostaglandins do not mediate interferon-alpha effects on mouse behavior. Physiol Behav 51:349-352, 1992
43. De Sarro GB, Masuda Y, Ascioti C, et al: Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone. Neuropharmacology 29:167-179, 1990
44. Morikawa O, Sakai N, Obara H, et al: Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349:317-324, 1998
45. Raber J, Koob GF, Bloom FE: Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: Comparison with the hypothalamic response. Neurochem Int 30:455-463, 1997
46. Shuto H, Kataoka Y, Horikawa T, et al: Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747:348-351, 1997